Ente Ospedaliero Ospedali Galliera
Quick facts
Marketed products
- MET · Endocrinology / Diabetes
MET is a metformin-based antidiabetic agent that reduces hepatic glucose production and improves insulin sensitivity.
Phase 3 pipeline
- Neridronate · Bone
Phase 2 pipeline
- BNT162b2 mRNA Covid-19 Vaccine · Immunology
BNT162b2 mRNA Covid-19 Vaccine works by instructing cells to produce a piece of the SARS-CoV-2 virus, prompting an immune response without causing the disease.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Ente Ospedaliero Ospedali Galliera portfolio CI brief
- Ente Ospedaliero Ospedali Galliera pipeline updates RSS
Frequently asked questions about Ente Ospedaliero Ospedali Galliera
What are Ente Ospedaliero Ospedali Galliera's marketed drugs?
Top marketed products include MET.
What is Ente Ospedaliero Ospedali Galliera's pipeline?
Ente Ospedaliero Ospedali Galliera has 1 drugs in Phase 3, 1 in Phase 2, 2 in Phase 1. Late-stage candidates include Neridronate.
Related
- MET · Endocrinology / Diabetes
- Sector hub: All tracked pharma companies